Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile

American Journal of Pathology

Volumn 165, Issue 5, 2004, Pages 1543-1556

  Liu, Alvin Y ^a   Roudier, Martine P ^a   True, Lawrence D ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALPHA2 INTEGRIN; ALPHA6 INTEGRIN; ANTIGEN; BETA1 INTEGRIN; CD104 ANTIGEN; CD164 ANTIGEN; CD24 ANTIGEN; CD38 ANTIGEN; CD57 ANTIGEN; CD63 ANTIGEN; CD75S ANTIGEN; CELL SURFACE MARKER; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HERMES ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MEMBRANE ANTIGEN; MICROSOMAL AMINOPEPTIDASE; NERVE GROWTH FACTOR RECEPTOR; THY 1 ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BASAL CELL; CANCER CELL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL LINEAGE; CELL POPULATION; CONTROLLED STUDY; EPITHELIUM CELL; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; SECRETORY CELL;

EID: 7244243811     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63412-8     Document Type: Article

References (52)

1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer Statistics 2000. CA Cancer J Clin 2000, 50:7-33
2. Kronz JD, Silberman MA, Allsbrook WC, Bastacky SI, Burks RT, Cina SJ, Mills SE, Ross JS, Sakr WA, Tomaszewski JE, True LD, Ulbright TM, Weinstein MW, Yantiss RK, Young RH, Epstein JI: Pathology residents' use of a Web-based tutorial to improve Gleason grading of prostate carcinoma on needle biopsies. Hum Pathol 2000, 31:1044-1050
3. Khoo VS, Pollack A, Cowen D, Joon DL, Patel N, Terry NHA, Zagars GK, von Eschenbach AC, Meistrich ML, Troncoso P: Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 1999, 41:166-172
4. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412:822-826
5. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629
6. Liu AY, Nelson PS, van den Engh G, Hood L: Human prostate epithelial cell-type cDNA libraries and prostate expression patterns. Prostate 2002, 50:92-103
7. Liu AY, True LD: Characterization of prostate cell types by CD cell surface molecules. Am J Pathol 2002, 160:37-43
8. Liu AY, Peehl DM: Characterization of cultured human prostatic epithelial cells by cluster designation antigen expression. Cell Tissue Res 2001, 305:389-397
9. Liu AY, LaTray L, van den Engh G: Changes in cell surface molecules associated with in vitro culture of prostatic stromal cells. Prostate 2000, 45:303-312
10. Liu AY: Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 2000, 60:3429-3434
11. Liu AY, True LD, LaTray L, Ellis WJ, Vessella RL, Lange PH, Higano CS, Hood L, van den Engh G: Analysis and sorting of prostate cancer cell types by flow cytometry. Prostate 1999, 40:192-199
12. Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, Lange PH, Hood L, van den Engh G: Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci USA 1997, 94:10705-10710
13. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso C, Palotie AV, Belldegrun AS: Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003, 55:71-80
14. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M: AJCC Cancer Staging Handbook. Springer-Verlag, New York, NY, 2002
15. Wikström P, Lissbrant IF, Stattin P, Egevad L, Bergh A: Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002, 51:268-275
16. Bonkhoff H, Stein U, Remberger K: Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994, 25:42-46
17. Okada H, Tsubura A, Okamura A, Senzaki H, Naka Y, Komatz Y, Morii S: Keratin profiles in normal/hyperplastic prostates and prostate carcinoma. Virchows Arch A Pathol Anat 1992, 421:157-161
18. Rubin MA, de La Taille A, Bagiella E, Olsson CA, O'Toole KM: Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia. Am J Surg Pathol 1998, 22:840-848
19. Potter VR: Phenotypic diversity in experimental hepatomas: the concept of partially blocked ontogeny. Br J Cancer 1978, 38:1-23
20. Shipp MA, Richardson NE, Sayre PH, Brown NR, Masteller EL, Clayton LK, Ritz J, Reinherz EL: Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. Proc Natl Acad Sci 1988, 85:4819-4823
21. Look AT, Ashmun RA, Shapiro LH, Peiper SC: Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest 1989, 83:1299-1307
22. Nelson JB, Carducci MA: Small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer. Cancer Invest 2000, 18:87-96
23. Joshi DD, Dang A, Yadav P, Qian J, Bandari PS, Chen K, Donnelly R, Castro T, Gascon P, Haider A, Rameshwar P: Negative feedback on the effects of stem cell factor on hematopoiesis is partly mediated through neutral endopeptidase activity on substance P: a combined functional and proteomic study. Blood 2001, 98:2697-2706
24. Moody TW, Mayr CA, Gillespie T, Davis TP: Neurotensin is metabolized by endogenous proteases in prostate cancer cell lines. Peptides 1998, 19:253-258
25. di Sant'Agnese PA: Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects. Urology 1998, 51(Suppl 5A):121-124
26. Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM: Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998, 4:50-57
27. Best CJM, Leiva IM, Chuaqui RF, Gillespie JW, Duray PH, Murgai M, Zhao Y, Simon R, Kang JJ, Green JE, Bostwick DG, Linehan WM, Emmert-Buck MR: Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn Mol Pathol 2003, 12:63-70
28. Gohring B, Holzhausen HJ, Meye A, Heynemann H, Rebmann U, Langner J, Riemann D: Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. Int J Mol Med 1998, 2:409-414
29. Shipp MA, Tarr GE, Chen C, Switzer SN, Hersh LB, Stein H, Sunday ME, Reinherz EL: CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci USA 1991, 88:10662-10666
30. Bogenrieder T, Finstad CL, Freeman RH, Papandreou CN, Scher HI, Albino AP, Reuter VE, Nanus DM: Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate 1997, 33:225-232
31. Fogel M, Friederichs J, Zeller Y, Husar M, Smirnov A, Roitman L, Altevogt P, Sthoeger ZM: CD24 is a marker for human breast carcinoma. Cancer Lett 1999, 143:87-94
32. Kramer G, Steiner G, Födinger D, Fiebiger E, Rappersberger C, Binder S, Hofbauer J, Marberger M: High expression of a CD38-like molecule in normal prostatic epithelium and its differential loss in benign and malignant disease. J Urol 1995, 154:1636-1641
33. - hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cells. Leuk Lymphoma 2002, 43:377-384
34. Epstein AL, Marder RJ, Winter JN, Fox RI: Two new monoclonal antibodies (LN-1, LN-2) reactive in B5 formalin-fixed, paraffin-embedded tissues with follicular center and mantle zone human B lymphocytes and derived tumors. J Immunol 1984, 133:1028-1036
35. Mane SM, Marzella L, Bainton DF, Holt VK, Cha Y, Hildreth JEK, August JT: Purification and characterization of human lysosomal membrane glycoproteins. Arch Biochem Biophys 1989, 268:360-378
36. Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP, Bubendorf L: Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003, 55:20-29
37. Zellweger T, Niuck C, Mirlacher M, Koivisto PA, Bloch M, Mihatsch MJ, Gasser TC, Bubendorf L: Expression patterns of potential therapeutic targets in prostate cancer. J Urol 2003, 169 5:213
38. Tawfic S, Niehans GA, Manivel JC: The pattern of CD10 expression in selected pathologic entities of the prostate gland. Hum Pathol 2003, 34:450-456
39. Sumitomo M, Shen R, Walburg M, Dai J, Geng Y, Navarro D, Boileau G, Papandreou CN, Giancotti FG, Knudsen B, Nanus DM: Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 2000, 106:1399-1407
40. Yao T, Takata M, Tustsumi S, Nishiyama K, Taguchi K, Nagai E, Tsuneyoshi M: Phenotypic expression of gastrointestinal differentiation markers in colorectal adenocarcinomas with liver metastasis. Pathology 2002, 34:556-560
41. Kanitakis J, Narvaez D, Claudy A: Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res 2002, 12:241-244
42. Saiki I, Fujii H, Yoneda J Abe F, Nakajima M, Tsuruo T, Azuma I: Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 1993, 54:137-143
43. Tokuhara T, Adachi M, Hashida H, Ishida H, Taki T, Higashiyama M, Kodama K, Tachibana S, Sasaki S, Miyake M: Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg 2001, 49:489-496
44. Tso C, McBride WH, Sun J, Patel B, Tsui K, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A: Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 2000, 6:220-233
45. + cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer 1996, 65:85-89
46. Hayward SW, Haughney PC, Rosen MA, Greulich KM, Weier HU, Dahiya R, Cunha GR: Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model. Differentiation 1998, 63:131-140
47. Shima H, Tsuji M, Elfman F, Cunha GR: Development of the male urogenital epithelia elicited by soluble mesenchymal factors. J Androl 1995, 16:233-241
48. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999, 59:5002-5011
49. Hayward SW, Grossfeld GD, Tlsty TD, Cunha GR: Genetic and epigenetic influences in prostatic carcinogenesis. Int J Oncol 1998, 13:35-47
50. Olapade-Olaopa EO, MacKay EH, Taub NA, Sandhu DPS, Terry TR, Habib FK: Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clin Cancer Res 1999, 5:569-576
51. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR: Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002, 8:2912-2923
52. Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE, Schlom J: In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990, 82:1191-1197